Haplotype phasing of CYP2D6: an allelic ratio method using Agena MassARRAY data.

Area of Science:

• Genetics
• Pharmacogenomics
• Molecular Biology

Background:

• Pharmacogenomics personalizes drug prescribing using individual genetic information.
• CYP2D6 is a crucial pharmacogene influencing drug metabolism and treatment outcomes.
• Current methods for CYP2D6 genetic analysis have limitations in phasing haplotypes for individuals with multiple gene copies.

Purpose of the Study:

• To develop and validate a novel protocol for CYP2D6 haplotype phasing using Agena MassARRAY data.
• To overcome limitations in analyzing complex CYP2D6 gene copy number variations.
• To enhance the clinical utility of pharmacogenomic testing for CYP2D6.

Main Methods:

• Application of a new protocol for CYP2D6 haplotype phasing on Agena MassARRAY generated data.
• Testing the protocol on samples with known and unknown CYP2D6 gene copy numbers.
• Validation against prior consensus data and assessment of hybrid tandem configurations.

Main Results:

• Achieved 100% concordance with prior data for CYP2D6 haplotype phasing in samples with multiple gene copies.
• Successfully resolved gene copy numbers for two out of three reference samples with unknown copy numbers.
• Demonstrated applicability to CYP2D6 hybrid tandem configurations.

Conclusions:

• The new protocol enables accurate CYP2D6 haplotype phasing, even with complex gene arrangements.
• This advancement improves the reliability of pharmacogenomic testing for CYP2D6.
• Enhanced CYP2D6 genotyping supports more precise personalized medicine approaches.